Effect Of Alpha Lipoic Acid And Captopril In Induced Atherosclerosis In Rabbits
DOI:
https://doi.org/10.63682/jns.v14i25S.6000Keywords:
Atherosclerosis, alpha-lipoic acid, captopril, oxidative stress, inflammationAbstract
Study beneficial effect of alpha lipoic acid and Captopril on atherosclerotic rabbits. Atherosclerosis, a leading cause of cardiovascular diseases, is a chronic inflammatory condition characterized by the accumulation of lipids and fibrous elements in the arterial walls. This review evaluates the therapeutic potential of alpha-Alpha lipoic acid (ALA) and captopril, both individually and in combination, in a rabbit model of induced atherosclerosis. ALA, a potent antioxidant, combats oxidative stress and inflammation, while captopril, an angiotensin-converting enzyme (ACE) inhibitor, reduces vascular remodeling and lowers blood pressure. Experimental studies in rabbits with diet-induced atherosclerosis have demonstrated that ALA significantly reduces oxidative stress markers, improves lipid profiles, and enhances endothelial function. Similarly, captopril mitigates vascular inflammation, decreases arterial stiffness, and regulates blood pressure. When co-administered, ALA and captopril exhibit synergistic effects by addressing multiple pathological pathways of atherosclerosis, including oxidative stress, inflammation, and hemodynamic changes.
This review synthesizes current evidence, highlighting the mechanisms through which ALA and captopril confer protective effects against atherosclerosis. Additionally, it explores the impact of this combination therapy on pharmacokinetic parameters, such as Cmax and Tmax, suggesting potential modifications in drug absorption and bioavailability due to co-administration. The findings underscore the therapeutic value of combining antioxidants and ACE inhibitors in managing atherosclerosis and offer insights into their translational potential for clinical applications.
Downloads
Metrics
References
Al-Okaily BN 2024. Unveiling the mysteries of oxidative stress: an insightful review of recent studies. J. Anim. Health Prod. 12(3): 395-412. DOI | ttp://dx.doi.org/10.17582/journal.jahp/2024/12.3.395.412 ISSN (Online) | 2308-2801.
Al-Okaily BN and H.F. Murad 2021. Role of alpha lipoic acid in protecting testes of adult rats from lead toxicity Iraqi Journal of Veterinary Sciences, Vol. 35, No. 2, 2021 (305-312) DOI: 10.33899/ijvs.2020.126814.1386.
Al-Ani, M. M., and H. F. Hasan. 2022. Cardiovascular and cytogenetics complications of obesity induced by monosodium glutamate in newborn male albino rats. NeuroQuantology – 20(4): 104–112. https://doi.org/ 10.14704/nq.2022.20.4.NQ22100.
Rwayyih, H. S., and T. S. S. Al-Azawi. 2024. Ameliorating cardiovascular disorders after ovariectomy by alpha-lipoic acid supplementation. Advances in Animal and Veterinary Sciences – 12(6): 1041–1046.
Ali, F. A. Y., and H. F. Hasan. 2024. Effect of alpha-lipoic acid on pharmacokinetics of captopril in induced atherosclerosis rabbits. African Journal of Biomedical Research – 27(3): 2607–2613. https://doi.org/ 10.53555/AJBR.v27i3.5972.
Abdulla, J. M., and B. N. Al-Okaily. 2022. Ameliorating testicular antioxidant status in rats exposed to hydrogen peroxide by resveratrol supplement. Biochemical and Cellular Archives – 22: 1895–1901. https://connectjournals.com/03896.2022.22.1895.
Alqayim, M. A. J., and M. K. Jabbar. 2015. Role of CDX2 upregulation in intestinal development and homeostasis in neonatal rats fed with Lactobacillus acidophilus. Journal of Pharmacy and Biological Sciences – 10(2): 136–146.
Abdalhameed, Z. F., and O. M. S. Ibrahim. 2024. The role of cytochrome P450 and organic anion transporting polypeptide on interaction of atorvastatin and macrolides in hyperlipidemic rabbits. African Journal of Biomedical Research – 27(3): 1563–1572.
Brem J, van Berkel SS, Zollman D, Lee SY, Gileadi O, McHugh PJ, ( 2016). "Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers". Antimicrobial Agents and Chemotherapy. 60 (1): 142–150.
Byrne, M. (2016). An investigation of epigenetic effects in Atherosclerosis. Of PHD. Thesis of Trinity College/ University of Dublin.
Capece, U., Moffa, S., Improta, I., Di Giuseppe, G., Nista, E. C., Cefalo, C. M. A., Cinti, F., Pontecorvi, A., Gasbarrini, A., Giaccari, A., & Mezza, T. (2022). Alpha-Alpha lipoic acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features. Nutrients, 15(1), 18.
Catapano, F. M. Maggi, and E. Tragni, (2000). “Low density lipoprotein oxidation, antioxidants, and atherosclerosis,” Current Opinion in Cardiology, vol. 15, no. 5, pp. 355–363.
Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM. (2018) First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. Nov 14;11(11):CD008170.
Cheng, F., Torzewski, M., Degreif, A., Rossmann, H., Canisius, A., & Lackner, K. J. (2013). Impact of glutathione peroxidase-1 deficiency on macrophage foam cell formation and proliferation: implications for atherogenesis. PloS one, 8(8), e72063.
Gan Z, Huang D, Jiang J, Li Y, Li H, Ke Y.(2018) Captopril alleviates hypertension-induced renal damage, inflammation, and NF-κB activation. Braz J Med Biol Res. 2018 Sep 03;51(11):e7338.
Goraca, P. Kleniewska,M. Kolodziejczyk, B. Skibska, (2015). "The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 63, no. 1, pp. 41–52.
.Hatmi, Z. N.;Saeid, A. K.;Broumand, M. A.;Khoshkar, S. N. and Danesh, Z. F. (2010). Multiple inflammatory prognostic factors in acute coronary syndromes: a prospective inception cohort study. Acta Medica Iranica, 48(1), 51.
Herman LL, Padala SA, Ahmed I, Bashir K. (2023) StatPearls StatPearls Publishing; Treasure Island (FL): Jul 31. Angiotensin-Converting Enzyme Inhibitors (ACEI)
Lezama-Martinez D, Flores-Monroy J, Fonseca-Coronado S, Hernandez-Campos ME, Valencia-Hernandez I, Martinez-Aguilar L.(2018) Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems. J Cardiovasc Pharmacol. Dec;72(6):291-295.
Libby, P.;Ridker, P. M. andHansson, G. K. (2009). Inflammation in atherosclerosis:from pathophysiology to practice. Journal of the American College of Cardiology,54(23), 2129-2138.
Lopéz, M. L.;Bruges, G.;Crespo, G.;Salazar, V.;Deglesne, P.-A.;Schneider, H.;Cabrera-Fuentes, H.;Schmitz, M. L. and Preissner, K. T. (2014). Thrombinselectively induces transcription of genes in human monocytes involved ininflammation and wound healing. Thromb Haemost, 112(5), 992-1001.
Minqin R, Watt F, Tan Kwong Huat B, Halliwell B. (2003). Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radic Biol Med; 34:746e52.
Marte F, Sankar P, Cassagnol M.(2022): Captopril. In: StatPearls. StatPearls Publishing, Treasure Island (FL);. PMID: 30571007.
Setorki M, Nazari B, Asgary S, Azadbakht L, Rafieian-Kopaei M (2011). Anti atherosclerotic effects of verjuice on hypocholesterolemic rabbits. Afr J Pharm Pharmacol. ; 5:1038–45.
Segall, M. Sosa, A. Alami et al., , (2004)“.Stability study of Alpha lipoic acid in the presence of vitamins A and E in o/w emulsions for cosmetic application,” Journal of Cosmetic Science, vol. 55, no. 5, pp. 449–461.
Sola, M. Q. S. Mir, F. A. Cheema et al., (2005) “Irbesartan and Alpha lipoic acid improves endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Alpha lipoic acid in Endothelial Dysfunction (ISLAND) study,” Circulation, vol. 111, no. 3, pp. 343–348.
Sinha, Nakshi; Kumar Dabla,( 2015): Pradeep Current Hypertension Reviews, Volume 11, Number 2, , pp. 132-142(11)
Smith AR, Shenvi SV, Widlansky M, (2004): Alpha lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem.;11:1135–46.
Smith CG, Vane JR (2009). "The discovery of captopril". FASEB Journal. 17 (8): 788–789.
Teichert, J; Hermann, R; Ruus, P; Preiss, R (2013). "Plasma kinetics, metabolism, and urinary excretion of alpha-Alpha lipoic acid following oral administration in healthy volunteers". Journal of Clinical Pharmacology. 43 (11): 1257–67.
Torzewski, M., Ochsenhirt, V., Kleschyov, A. L., Oelze, M., Daiber, A., Li, H., ... & Lackner, K. J. (2018). Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arteriosclerosis, thrombosis, and vascular biology, 27(4), 850-857.
Vallerand AH, Sanoski CA, Deglin JH (2015-06-05). Davis's drug guide for nurses (Fourteenth ed.)
Ying, Z., Kherada, N., Farrar, B., Kampfrath, T., Chung, Y., Simonetti, O., Deiuliis, J., Desikan, R., Khan, B., Villamena, F., Sun, Q., Parthasarathy, S., & Rajagopalan, S. (2010). Alpha lipoic acid effects on established atherosclerosis. Life sciences, 86(3-4), 95–102.
Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC (2008), Dietary alpha-Alpha lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation.; 117(3):421–8.
Zhang, G.;Chen, M.;Yu, Z.;Wang, X. and Wang, Z. (2014). Relation between neutrophil-to-lymphocyte ratio and severity of coronary artery stenosis. Genet Mol Res, 13(4), 9382-9389.
Wang, L., & Witztum, J. L. (2004). The role of oxidized lipoproteins in atherosclerosis. Current Opinion in Lipidology, 15(5), 396-401.
Akiyama, T., & Ivanov, A. I. (2024). Mechanisms of oxidized LDL-mediated endothelial dysfunction and atherosclerosis. Frontiers in Cardiovascular Medicine.
Kattoor, J. J., et al. (2025). Treatment of endothelial cell dysfunction in atherosclerosis. Frontiers in Physiology.
Loffredo, L., & Carnevale, R. (2024). Endothelial dysfunction: Redox imbalance, NLRP3 inflammasome, and atherosclerosis. Antioxidants.
Lusis, A. J. (2024). Atherosclerosis. Nature Reviews Disease Primers.
Wang, L., & Witztum, J. L. (2004). The role of oxidized lipoproteins in atherosclerosis. Current Opinion in Lipidology, 15(5), 396-401.
Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868-874.
Gibbons, R. J., & Alexander, R. W. (2007). Captopril: A review of its clinical efficacy and use in the treatment of hypertension and heart failure. Journal of the American College of Cardiology, 49(3), 363-370.
Miller, A. R., et al. (2015). Pharmacodynamics and mechanisms of action of captopril in cardiovascular conditions. European Journal of Clinical Pharmacology, 71(8), 937-947.
Zhou, Y., et al. (2019). The efficacy of captopril in improving heart failure symptoms and survival rates. Journal of Cardiovascular Pharmacology and Therapeutics, 24(4), 337-345.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
